About C4 Therapeutics
C4 Therapeutics is a company based in Cambridge (United States) founded in 2016 by Marc A Cohen. C4 Therapeutics has raised $223 million across 4 funding rounds from investors including Novartis, Janus Henderson Investors and RTW Investments. The company has 110 employees as of December 31, 2024. C4 Therapeutics offers products and services including Cemsidomide, CFT1946, and CFT8919. C4 Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Erasca, MiRagen, Mereo BioPharma and Nimbus Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 110 as on 31 Dec, 2024
- Founders Marc A Cohen
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name C4 Therapeutics, Inc.
-
Annual Revenue
$35.58 M (USD)71.44as on Dec 31, 2024
-
Net Profit
-$105.32 M (USD)20.51as on Dec 31, 2024
-
EBITDA
-$109.28 M (USD)16.76as on Dec 31, 2024
-
Total Equity Funding
$223 M (USD)
in 4 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Jan 04, 2024
-
Investors
Novartis
& 23 more
-
Employee Count
110
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of C4 Therapeutics
C4 Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CCCC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of C4 Therapeutics
C4 Therapeutics offers a comprehensive portfolio of products and services, including Cemsidomide, CFT1946, and CFT8919.
Therapy that degrades proteins to treat diseases.
Protein degradation treatment for targeted medical applications.
Innovative drug using protein degradation for disease management.
People of C4 Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
35 people
Software Development Team
10 people
Clinical Team
4 people
Scientific Team
4 people
Human Resources and Administration
3 people
Legal and Compliance
2 people
Senior Team
2 people
Principal Team
1 people
Unlock access to complete
Funding Insights of C4 Therapeutics
C4 Therapeutics has successfully raised a total of $223M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in C4 Therapeutics
C4 Therapeutics has secured backing from 24 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, Janus Henderson Investors and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Investment firm backed by the Cohen family
|
Locked | Locked | Locked | |
|
Early-stage investments are targeted by Axil Capital, a VC firm.
|
Locked | Locked | Locked |
Investor details for C4 Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by C4 Therapeutics
Investment portfolio details for C4 Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - C4 Therapeutics
Detailed financials for C4 Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
C4 Therapeutics Comparisons
Peer comparison for C4 Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of C4 Therapeutics
C4 Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Erasca, MiRagen, Mereo BioPharma and Nimbus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of C4 Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on C4 Therapeutics
Complete news archive for C4 Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about C4 Therapeutics
C4 Therapeutics was founded in 2016.
C4 Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
C4 Therapeutics is a funded company, having raised a total of $223M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at C4 Therapeutics is 110.
Annual revenue of C4 Therapeutics is $35.58M as on Dec 31, 2024.
C4 Therapeutics was established in 2016 and is based in Cambridge, United States. Focus is placed on the biotechnology sector, where small-molecule therapeutics are created to address cancer. The Degronimid platform is employed to design binders that selectively target problematic proteins, enabling their degradation through the cellular proteasome pathway. Development efforts include CFT7455 aimed at hematologic malignancies, CFT8634 for sarcoma, and a BRAF V600E inhibitor for solid tumors.
C4 Therapeutics's top competitors include Jazz Pharmaceuticals, Erasca and Nimbus Therapeutics.
C4 Therapeutics offers Cemsidomide, CFT1946, and CFT8919.
Yes, C4 Therapeutics is publicly traded on NASDAQ under the ticker symbol CCCC.
C4 Therapeutics has 24 investors. Key investors include Novartis, Janus Henderson Investors, RTW Investments, RA Capital, and Perceptive Advisors.
The ticker symbol of C4 Therapeutics is CCCC on NASDAQ.